


Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) - Commercial Research Delivery Investment Programme

Overview



Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG)

£400 million investment over 5 years until 31 December 2028 to drive forward UK innovation, sustainability and growth (Investment Programme). The programme will be ringfenced to support work in:

- 1. Pioneering clinical trials - bolstering the NHS's capacity to deliver commercial clinical research (£300M)**
2. Manufacturing - positioning the UK at the forefront of sustainable manufacturing by driving innovative advancements in environmental technologies and cultivating strategic partnerships [Innovate UK]
3. Innovative health technology assessments - supporting access to innovative medicines by developing novel approaches to health technology assessment challenges

Stream 1: Expand on and enhance existing dedicated commercial clinical research infrastructure across the UK Each nation may have a different solution but all will be branded as a UK network

Stream 2: Deliver flexible funding to pump prime clinical trial resources, by increasing workforce capacity and infrastructure relevant to the delivery of commercial clinical research

**£22.1 million for Wales
over 5 years**

Announced 28 August 2024

[ABPI Website](#) / [Media](#) / [UK secures £400 million investment to boost clinical trials](#)

UK secures £400 million investment to boost clinical trials

28 August 2024 Posted in News by Press Office

- Up to £400 million of investment will support faster patient access to cutting-edge treatments, strengthen clinical trials and improve medicines manufacturing in the UK
- 18 new clinical trials hubs will be created across UK to accelerate research

NHS patients will have earlier access to new treatments and the UK will become the home of cutting-edge health research as the UK Government launches a joint public-private investment programme worth up to £400 million.

The Voluntary Scheme for Branded Medicine Pricing, Access, and Growth (VPAG) Investment Programme opens today. It will channel significant investment into the UK's health and life sciences sector over the next five years, boosting economic growth and the global competitiveness of the UK's life sciences sector.

It is the first major public-private partnership through supporting the development of new medicines from labs to wards.

[Home](#) > [Health and social care](#) > [Medicines, medical devices](#) > [Clinical trials and investigations](#)

Press release

UK secures £400 million investment to boost clinical trials


World-first public-private collaboration launched to kickstart economic growth and build an NHS fit for the future.

Mark Drakeford, the Welsh Government's Cabinet Secretary for Health and Social Care, said:

This investment programme is an exciting opportunity to further enhance the UK life sciences sector. We are delighted to play our part in this to advance the cutting-edge of pharmaceutical and technological developments, which will ultimately deliver real benefits to healthcare and patient care.

VPAG Funding to Wales (Clinical Trials)

£22.1million over 5 years




Current Position

ABPI reports (September 2021 and November 2023) show Wales activity is consistently lower per capita every year, compared to other nations ([ABPI report](#))




High level Plan - Commercial Research Delivery Wales (CRDW)

- Networked One Wales commercial research delivery service - formal 'collective' between NHS Wales connected and overseen by a One Wales national coordination hub
- Wales dedicated clinical research facilities and infrastructure will form the Wales Clinical Research Delivery Centre
- Facilities (mobile and fixed) in community and primary care to maximise access for participants across geographies
- Receipt of VPAG funding to Wales is conditional on compliance with ABPI and UK agreed requirements (NCVR, UK KPIs, full financial transparency of commercial income)



Wales Commercial Research Delivery Centre (Wales CRDC)

- Clinical Research Facilities connected through a **One Wales** national coordination hub, providing:
 - Connection to the UK CRDC Network
 - One Wales operational/clinical leadership and business management:
 - Networked local capacity and capability
 - Facilitated rapid study set-up and delivery related logistics:
 - Data enabled feasibility and study placement coordination
 - Coordination of study set-up
 - All-Wales costing/contracting service
 - All-Wales Medical Genomics Service (AWMGS)
 - National remote study delivery services (clinic booking, screening services, medical on call rota)
- Wales CRDC is integrated into Wales's wider Commercial Research Delivery Wales (CRDW) infrastructure



Wales CRDC Facilities and Infrastructure Funding Call

Purpose: To increase commercial research delivery capacity by expanding on and enhancing existing dedicated commercial clinical research facilities that are part of the Wales Commercial Research Delivery Centre (Wales CRDC).

Examples: Requesting funding to build on established areas of strength and expertise and have the capacity and infrastructure to respond quickly and meet the expectations set by UK CRDC

Eligible: Members of the Wales CRDC, stakeholders wishing to become members of Wales CRDC

Timelines

- Call opened 10th Jan 2025
- Application deadline 31st Jan 2025
- Applicants informed of outcome late Feb 2025



Ymchwil Iechyd
a Gofal Cymru
Health and Care
Research Wales

Commercial Clinical Trial Capacity and Capability Funding call

Purpose: Funding to pump prime clinical trial resources, by increasing workforce capacity and infrastructure as well providing agility relevant to the set up and delivery of commercial clinical research

Eligible: Anyone who seeks to increase the capacity and capability of commercial research delivery within the NHS e.g all specialties, specialist services, clinical research infrastructure within HEIs)

Examples: Request funding to increase staff capacity for a specific pipeline, fund equipment that is required to demonstrate capability for specific commercial trials

Timelines

- Call open 17 Jan 2025
- Application deadline 7 Feb 2025
- Applicants informed of outcome late February